BlueWillow Biologics is a privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines, based on its patented nanotechnology platform. The company was originally founded as NanoBio Corporation, a spin-off from the Center for Biologic Nanotechnology at the University of Michigan, and was initially focused on developing nano-scale dermatology applications. Based on promising research generated under several Gates Foundation and NIH contracts, the company underwent a strategic “pivot” in 2016–17 to refocus its nanotechnology platform on the development of intranasal vaccines for respiratory and sexually transmitted diseases.

Research Grants 13 show all


$500K
2015

$2.3M
2016

$3.8M
2017

$910.2K
2018

$299.8K
2019

Patents 120show all

  • 50
    A61K - Preparations for medical, dental, or toilet purposes
  • 17
    C12N - Microorganisms or enzymes
  • 8
    Y02A - Technologies for adaptation to climate change
  • 7
    A61Q - Specific use of cosmetics or similar toilet preparations
  • 7
    C06B - Explosives or thermic compositions
  • 6
    B23K - Soldering or unsoldering
  • 6
    H01R - Line connectors
  • 5
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 5
    B32B - Layered products, i.e. products built-up of strata of flat or non-flat, e.g. cellular or honeycomb, form
  • 4
    A01N - Preservation of bodies of humans or animals or plants or parts thereof

Clinical Trials 8show all

3Phase 13Phase 32Phase 2

SEC Filings show all


6
D

Contact Information

2311 Green Road Suite A
Ann Arbor, MI 48105
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$98,300,00011-502018-09-26Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2018-09-26GrantSmall Business Innovation Research
2013-10-29$5,500,000GrantNational Institute of Allergy and Infectious Diseases
2018-05-07$10,000,000Series ANorth Coast Technology InvestorsLine Moon Ventures, University of Michigan MINTS fund
2016-02-04$1,800,000Convertible Note
2006-10-21$30,000,000Series APerseus
2010-11-30$6,000,000GrantBill & Melinda Gates Foundation
2009-02-18$12,000,000Series BPerseus
2017-03-06GrantSmall Business Innovation Research
2012-11-28$11,000,000Series CVenture Investors, Perseus
2009-07-08$22,000,000Series BVenture InvestorsPerseus

SEC Form D Funding Events

DateOfferedSoldType
2009-05-29Indefinite$10,000,000Other
2008-12-11Unknown Unknown Other (Paper Filing)

Key Executives

  • James R. Baker, Jr.
    Executive Officer
  • David Peralta
    Executive Officer
  • Norman C. Selby
    Director
  • Ronald M. Cresswell
    Director
  • Daniel B. Dubin
    Director
  • Robert C. Moellering
    Director
  • David M. Stout
    Director